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 ABSTRACT
Among thrombotic microangiopathies (TMA), the hemolytic uremic syndrome associated with dysregulation 
of the alternative complement pathway (aHUS) is one of the most challenging diseases a nephrologist can 
face. By the end of the XXth century, the complement’s role was unraveled with the discovery that mutations 
in the factor H coding gene were responsible for aHUS. But it was the acknowledgment that pharmacological 
C5-9 blockage provided a cure for aHUS that fostered the interest of the nephrology community in the genet-
ics, pathophysiology and therapeutics of, not only of aHUS, but TMA in general. The molecular genetics of 
aHUS is technically demanding and, as such, in Portugal (alike many other European countries) a single labora-
tory emerged as a national reference center. The fact that all samples are evaluated in a single center provides 
a unique opportunity for data collection and a forum for discussion for all those interested in the field: immu-
nologists, molecular geneticists, pathologists and nephrologists. The current consensus document emerged 
from such a discussion forum and was sponsored by the Portuguese Society of Nephrology. The goal is more 
to portray the Portuguese picture regarding the diagnostic approach and therapeutic options than to exten-
sively review the state of the art of the subject. The accompanying documents that are published as supple-
mentary data are in line with that goal. They range from the informed consent and clinical form to be sent 
together with the biological samples for genetic testing, to the appendix regarding the actual sampling and 
storing conditions. The document is also intended to set an example for future documents and independent 
discussion forums on other kidney diseases for which emerging diagnostic and/or therapeutic strategies are 
reaching clinical practice.
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 INTRODUCTION
Thrombotic microangiopathy (TMA), hemolytic ure-
mic syndrome in particular, can be a devastating illness, 
with significant renal and non-renal morbidity and 
mortality. The awareness of the role played by com-
plement in the pathophysiology of atypical hemolytic 
uremic syndrome (aHUS)1-3 and the introduction, in 
2011, of a drug able to block the effects of complement 
system activation4 has dramatically changed the treat-
ment and the prognosis of this entity.
However, its differential diagnosis is still challenging 
and this is at odds with the need for a fast diagnosis 
and early initiation of treatment in order to minimize 
organ damage. Despite the publication of several inter-
national consensus documents5-8, a recent survey invol-
ving European medical staff, mostly nephrologists with 
more than 10 years of clinical practice, revealed that 
approximately half of clinicians stated that making a 
diagnosis of TMA would take 3 days; similarly, treatment 
was delayed for at least 3 days in 57% of cases and in 
13% of the cases for more than 1 week after presenta-
tion9. In this same survey, only 70 and 78% of the enqui-
red physicians requested complement evaluation and 
ADAMTS13 (A Disintegrin and Metalloprotease with 
ThromboSpondin type 1 motif, member 13) activity in 
the initial medical workup, respectively9. This reinforces 
the need to establish clear guidelines that may increase 
national and regional awareness of TMA, its differential 
diagnosis, and the proper lab test prioritization accor-
ding to the local availability of these tests.
The Portuguese Society of Nephrology and the Socie-
ty of Pediatric Nephrology of the Portuguese Society 
of Pediatrics working group on aHUS aims at esta-
blishing National recommendations for the differential 
diagnosis and management of aHUS by reviewing cur-
rent definition and etiological classification of TMA, 
aHUS differential diagnosis and physiopathology as well 
an update on therapeutic management.
  OVERVIEW OF THROMBOTIC 
MICROANGIOPATHIES
Thrombotic microangiopathy describes the patho-
logical findings of microvascular endothelial injury and 
thrombosis. Originally introduced in 1952 by Sym-
mers(10), it described the vascular lesions seen in 
Thrombotic Thrombocytopenic Purpura (TTP); later, 
Habib11 included under the same designation the 
pathological observations of HUS; since then, it has 
been recognized that these changes are present in 
many other conditions (e.g. scleroderma renal crisis, 
malignant hypertension) and its use has become more 
widespread11. In the heart of its pathophysiology lies 
an imbalance between the immune, clotting and com-
plement systems, precipitated by environmental factors 
(prevalent in secondary TMAs) in the proper setting of 
genetic predisposition (prevalent in aHUS)12. Currently, 
this strictly pathological definition has evolved to a 
clinical diagnostic triad of a Coombs negative microan-
giopathic hemolytic anemia (MAHA), consumptive 
thrombocytopenia and platelet-mediated microvascu-
lar occlusion, leading to organ failure.
TMA classification can be both challenging and con-
fusing. Ancient designations are not always reconcilable 
with the ever-evolving knowledge on pathogenesis. 
Traditionally, HUS and TTP have been considered the 
two main variants of TMA. Around 90% of HUS cases 
were considered to be associated with infection by 
Shiga-Toxin producing Escherichia Coli (STEC), with the-
se commonly designated as typical or diarrhea (D+) 
HUS7. The remaining non-STEC cases were referred to 
as atypical HUS13. Finally, the latter were either consi-
dered as secondary aHUS, whenever a cause could be 
identified, or, if not the case, primary aHUS13. More 
recently, alternative pathway complement dysregula-
tion was found to underlie most aHUS cases and hence 
the designation of complement-mediated aHUS13. On 
the other hand, a deficit in the activity of the von Wil-
lebrand factor (VWF) cleaving protease ADAMTS13 is 
the hallmark of TTP; ultra large VWF multimers are 
formed, leading to platelet aggregation and microvas-
cular thrombosis14. These definitions are reflected in 
the Kidney Disease: Improving Global Outcomes (KDI-
GO) consensus document of 20166. In our paper we 
will designate complement mediated HUS as aHUS. We 
refrained from using the designation of secondary aHUS 
for TMA conditions once STEC-HUS, TTP and comple-
ment mediated HUS are excluded and chose to desig-
nate these conditions as secondary TMA.
Upon presentation, it is critical to identify plausible 
causes as well precipitating factors, in order to initiate 
supportive or specific therapy within the first 24-48h 
after patient admission5. In figure 1 we present the gene-
ral outline for the different diagnoses. Although the 
importance of a detailed clinical background (including 
family history and trigger events, such as infections and 
drug exposure) cannot be overemphasized, it is impor-
tant to realize that the underlying cause is rarely iden-
tifiable on clinical grounds alone5. Hence the reliance 
Ana Azevedo, Bernardo Faria, Catarina Teixeira, Fernanda Carvalho, Gisela Neto, Josefina Santos,  
Maria do Céu Santos, Nuno Oliveira, Teresa Fidalgo, Joaquim Calado
Port J Nephrol Hypert 2018; 32(3): 211-232    213
on multiple laboratory tests; in table 1 we present the 
key tests that should be ordered. We also reference Por-
tuguese labs where these tests are available.
The key presenting findings that should evoke the 
differential diagnoses of TMA are:
–  MAHA: low hemoglobin, elevated serum lactate 
dehydrogenase (LDH) level, undetectable (or mark-
edly decrease) serum haptoglobin and the pres-
ence of schistocytes on a peripheral blood smear 
(although a non-obligatory criteria) with negative 
Coombs test.
–  Thrombocytopenia;
–  Organ injury (kidney disease, neurologic symptoms, 
gastrointestinal manifestations or other);
–  Normal coagulation evaluation.
 Etio-pathogenic classification of TMA
Atypical HUS
Atypical HUS, caused by dysregulation of the alter-
native complement, is essentially, but not entirely, a 
diagnosis of exclusion; i.e. mainly to be considered after 
ruling out TTP or STEC-HUS by testing ADAMTS13 acti-
vity and culturing for STEC, respectively5. But, and as 
detailed below, although driven by dysregulation of 
the alternative complement pathway, only a fraction 
of aHUS cases will display a decrease in serum com-
plement components, C3 in particular, and in roughly 
half of them, mutations in genes encoding for the main 
regulatory proteins of the complement alternative 
pathway (or others) will not be identified. So, and 
although genotype and phenotype characterization of 
an aberrant alternative pathway complement are cri-
tically helpful for the diagnosis of aHUS, they will not 
be uniformly present in every single patient. In addition, 
even with the advent of the next generation sequencing 
technologies, genotype results can take several weeks1. 
Treatment, therefore, has to be initiated based on a 
high degree of suspicion; not only excluding TTP and 
STEC-HUS, but being aware that secondary TMAs do 
exist and that they clinically and histopathologically 
may overlap with aHUS. A prompt diagnose of aHUS 
at presentation is one of the most challenging tasks a 
nephrologist can face these days. But is also one of the 
most rewarding. The major focus of the manuscript, 
aHUS is detailed in section III.
Thrombotic Thrombocytopenic Purpura
Thrombotic Thrombocytopenic Purpura (TTP) has a 
reported incidence of six cases per million per year in 
the UK and a mortality rate of 90%, that can be reduced 
by the prompt delivery of plasma exchange (PEX) 15. 
It is probably the main primary TMA to be considered 
in an adult patient. Though there is a lower incidence 
in children, we recommend the determination of the 
activity level of ADAMTS13 and, eventually, anti ADA-
MTS13 antibodies, in adolescents13,16. The key lab test 
is ADAMTS13 activity: levels < 5-10% confirm the diag-
nosis; a level > 5-10% rules it out15,17. It is mandatory 
to collect samples prior to initiating any kind of plasma 
therapy: donor plasma ADAMTS13 activity may con-
found results and plasmapheresis may remove patients’ 
anti ADAMTS13 antibodies, both instances leading to 
false-negative results. Although central nervous symp-
toms are key to TTP and renal involvement argue 
against it, one must realize that up to 35% of patients 
do not have neurological signs at presentation and that 
modest renal impairment can be present in up to 50% 
of the patients15. Platelet count can help in discrimi-
nation: usually between 10-30.000/µL for PTT while 
50-100.000/µL for HUS15.
STEC-HUS
STEC-SHU is the major systemic complication of ente-
rohemorrhagic Siga-Toxin producing Escherichia Coli 
infection, usually serotype O157:H7. Routine investi-
gation for STEC-HUS is mandatory whenever diarrhea 
presents. Around 5% of STEC-HUS do not have a pro-
dromal diarrhea and 30% of complement mediated 
HUS do have diarrhea or gastroenteritis6. HUS compli-
cates 6-9% of overall STEC infections and about 15% if 
children under age 10 are considered18. Around appro-
ximately two-thirds of STEC-HUS cases in the United 
States occurred among children less than five years of 
age19 and is the most common cause of pediatric HUS, 
accounting for 90 percent of cases20. But it also needs 
to be considered in adults: in the O104:H4 outbreak in 
Germany, 88% of the patients were 18 years of age or 
older21. Clinical manifestations may include history of 
bloody diarrhea in the previous 5-10 days, a peripheral 
white blood cell count above 10.000/µL and abdominal 
tenderness. Fever is frequently absent18.
Secondary forms of TMA
Beyond the diagnoses discussed above, several other 
entities may be associated with TMA. We generally 
define these as secondary TMA (see Figure 1).
One of the most common conditions associated with 
TMA that needs to be considered is severe hyperten-
sion. The differential diagnosis is sometimes difficult 
since TMA caused by hypertension is undistinguishable 
from all the other entities that cause TMA; also, most 
patients with other TMAs such as TTP or aHUS also 
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present with new-onset severe hypertension. Hyper-
tension causing MAHA and thrombocytopenia is typi-
cally severe, with systolic pressures over 200 mmHg 
and diastolic pressures over 100 mmHg, and is asso-
ciated with severe kidney injury as well neurological 
symptoms related to posterior reversible encephalo-
pathy syndrome22. The key to the differential diagnosis 
is the evolution of the clinical condition: TMA secondary 
to hypertension should improve quickly with blood 
pressure control, without the need for plasma therapy 
or terminal complement blockage17.
Systemic infections must also be considered while 
evaluating TMA. In the Oklahoma Registry, between 
1989 and 2010, 31 (7%) of 415 patients were initially 
diagnosed as having TTP and therefore treated with 
PEX, but subsequently, the TMA was found to be secon-
dary to a systemic infection17.
Streptococcus pneumoniae TMA needs to be exclud-
ed, particularly in the pediatric population, since 5% 
of TMA cases in children are associated with Pneumo-
coccal invasive infections5. Children under 2 years have 
the highest incidence, similarly to other invasive pneu-
mococcal infections23. Though invasive Streptococcus 
pneumoniae infections are common, these are only 
complicated by TMA in 0.4 – 0.6% of patients but are 
often more serious in terms of morbidity and mortal-
ity23. The commonest precipitating illness for TMA is 
pneumococcal pneumonia with empyema (65–92%)24. 
Pneumococcal meningitis has been less commonly 
reported though most of the patients with worse neu-
rologic disease also presented with meningitis23. The 
clinical features can often cause confusion and delay 
in diagnosis due to a significant cross over with dis-
seminated intravascular coaguIation25. Approximately 
90% of patients have positive direct Coombs test 
results7. The epidemiology has changed with the emer-
gence of different pneumococcal serotypes as newer 
pneumococcal vaccines became available. Pneumococ-
cal 13-valent conjugate vaccine (Prevenar13®), included 
in our National Vaccination Program since 2015, is 
important to help prevent Streptococcus pneumoniae 
TMA. However, Prevenar13® protects against many but 
not all HUS-related serotypes. Pneumococcal 23-valent 
conjugate vaccine covers all strains but is not 
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Figure 1
TMAs diagnostic diagram
Figure 1 – TMAs diagnostic diagram
Abbreviations: ADAMTS13 - a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13;  aHUS - Atypical
hemolytic uremic syndrome; ANA - antinuclear antibodies; HA - hemolytic anemia; HIV - Human Immunodeficiency Virus; STEC - Shiga
toxin-producing Escherichia coli; TMA - thrombotic microangiopathy; TTP - thrombotic thrombocytopenic purpura; 
- - - In these cases a full complement evaluation should be performed  
Abbreviations: ADAMTS13 – a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13;  aHUS – Atypical hemolytic uremic syndrome; ANA – antinucle-
ar antibodies; HA – hemolytic anemia; HIV – Human Immunodeficiency Virus; STEC – Shiga toxin-producing Escherichia coli; TMA – thrombotic microangiopathy; TTP – thrombotic 
thrombocytopenic purpura; 
- - -  In these cases a full complement evaluation should be performed  
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recommended before 2 years of age. Although the 
pathogenesis of Streptococcus pneumoniae TMA 
remains uncertain, the Thomsen–Friedenreich antigen 
(T antigen) seems to play a central role23. Streptococcus 
pneumoniae produces neuraminidase, thereby expos-
ing the T antigen on the surface of cell membranes, 
leading to IgM antibody activation via reaction with a 
complement-fixing antibody, resulting in red cell poly-
agglutination and hemolysis26. Ruling out Pneumococ-
cal invasive infections is important since therapeutic 
plasma may aggravate the condition. Early identification 
of patients with Streptococcus pneumoniae TMA is 
critical so that fresh frozen plasma or plasma containing 
products for PEX may be avoided because most healthy 
donors will have anti–T IgM in their serum23,26. When 
Streptococcus pneumoniae infection is suspected or 
proven, it is recommended that washed blood products 
should be used23.
Autoimmune diseases can also be associated with 
TMA. The differential diagnosis may sometimes be diffi-
cult and there is a considerable overlap between enti-
ties12. Indeed, mutations of the complement system 
may be present in up to 33% of the patients that present 
with HUS associated with autoimmune diseases12.
Clinically evident TMA is rare in Systemic Lupus 
Erythematosus (SLE), but occasionally superimposes 
in the anti-phospholipid syndrome and scleroderma. 
In the case of SLE, TMA is mostly of histopathological 
nature. In a series of 149 SLE patients TMA was present 
in 36 (24.3%), but only 7 patients (4.7%) had associated 
clinical features: in the remaining 29 patients TMA was 
exclusively a pathological finding in kidney biopsies, 
but one associated with severity and worse renal prog-
nosis, as assessed by higher proteinuria, serum creati-
nine and total activity scores27. The pathogenesis of 
renal TMA in lupus nephritis remains unclear. SLE is an 
immune-complex mediated disease, so one can assume 
that the classical pathway drives TMA in lupus nephritis. 
Nevertheless, several studies suggest that the dysre-
gulation of the alternative complement pathway may 
play a role as well. For instances, nearly half of the 
patients with TMA features had decreased serum com-
plement factor H levels and this was related to higher 
activity indexes and poorer renal prognosis27. Antiphos-
pholipid syndrome (aPLS) can also manifest through 
TMA, particularly in patients with a catastrophic pre-
sentation, and successful use of eculizumab has been 
reported28. Finally Scleroderma Renal Crisis (SRC) may 
clinically and pathologically overlap with TMA, since, 
in addition to its clinical features of new onset severe 
hypertension and rising serum creatinine levels, MAHA 
is apparent in up to 50% of patients29. SRC is more 
likely to occur in patients with diffuse cutaneous sys-
temic sclerosis, usually within the first 3–5 years of 
onset29. Contrary to SLE or aPLS, in SRC, complement 
dysregulation does not appear to be involved in the 
pathogenesis, and treatment rests on blood pressure 
control through blockage of the renin angiotensin 
system29.
Drug induced TMA may be mediated by drug-depen-
dent antibodies reacting with platelets, neutrophils, 
and other cells, the best-documented case being qui-
nine17. Drugs may also cause TMA in a dose-dependent 
way17. Examples are mitomycin C, gemcitabine, calci-
neurin inhibitors (cyclosporine, tacrolimus [CNI]), mTOR 
inhibitors and vascular endothelial growth factor inhi-
bitors (bevacizumab).
Disseminated malignancies may also be an occasio-
nal cause of TMA. Oncology literature series suggest 
that probably any metastatic malignancy may cause 
TMA 30. In most reports, the systemic micro vascular 
tumor emboli is the proposed mechanism of TMA 17. 
Clues that may suggest the presence of systemic malig-
nancy include older age, weight loss, gradual onset of 
symptoms and peripheral leukoerythroblastosis17.
Among the cobalamin (Cbl) deficient inborn metabo-
lism errors, the combined methylmalonic acidemia and 
homocystinuria (also termed CblC type), is the most 
frequent. Although an extremely rare cause of TMA, 
CblC should always be considered, particularly in the 
pediatric ages31-33. Failure to thrive, poor feeding, 
lethargy and neurologic abnormalities are usually pre-
sent in infantile CblC-associated TMA31,32. However, 
late-onset in childhood and adulthood can occur. Par-
ticularly challenging is the late onset CblC presenting 
as isolated TMA in the absence of neurological involve-
ment34. Since serum total homocysteine determination 
is inexpensive and available in most hospital labs, we 
recommend that it should be performed at the initial 
workup of every TMA case, regardless of age or neuro-
logical involvement. If appropriate, the search for urine 
organic acids, serum methylmalonic acid (MMA) and 
plasma amino acids (low methionine levels) should 
follow. Molecular diagnosis can be accomplished by 
MMACHC gene sequencing. In Portugal, the MMACHC 
c.271dupA (p.Arg91Lysfs*14) allele is the most preva-
lent, either in homozygosity or compound heterozygo-
sity35. The treatment goal is to normalize serum methio-
nine and to lower homocysteine and MMA as soon as 
possible, which can be achieved through the adminis-
tration of hydroxocobalamin and betaine31,32.
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Pregnancy is associated with various forms of TMA, 
accruing significant perinatal and maternal morbidity 
and mortality36. The differential diagnosis of TMA in 
pregnancy primarily concerns aHUS and TTP, as well as 
the TMA occurring in the syndrome of hemolysis, ele-
vated liver enzymes, and low platelets (HELLP syndro-
me)37, which is part of the clinical spectrum of pree-
clampsia38. TMA occurring late in the third trimester 
or postpartum is usually caused by aHUS39-41. A high 
proportion (>50%) of these women will have identifia-
ble complement mutations, and pregnancy acts as a 
trigger in those with an underlying genetic predispo-
sition42. This provides the rationale for complement 
inhibition therapy, and increasing data suggests that 
eculizumab is safe during pregnancy43,44. According to 
KDIGO recommendations all patients with pregnancy-
-associated HUS should have a full complement eva-
luation. On the other hand, TMA that occur during 
pregnancy, particularly in the second and third trimes-
ters and resolve following pregnancy, are usually TTP. 
This might be explained by the physiologic increase in 
von Willebrand factor during pregnancy, which consu-
mes ADAMTS1342. Accordingly, on the basis of obser-
vational data and knowledge of pathogenesis, PEX is 
recommended45.
Although the etiology of HELLP and preeclampsia is 
not fully understood, it has been linked to elevated 
circulating antiangiogenic factors soluble Flt1 (sFlt1) 
and endogline. sFlt 1 reduces the concentration and 
activity of vascular endothelial growth factor (VEGF), 
leading to endothelial dysfunction, hypertension, and 
proteinuria37. There is some evidence that complement 
is activated in preeclampsia and HELLP, although it is 
unclear whether it plays a role in pathogenesis, and 
seems to be one of many predisposing factors rather 
than the main triggering event42 in contrast to preg-
nancy-associated aHUS. Management should be sup-
portive, and the definitive treatment of HELLP is expe-
dited delivery.
  Histopathological Features of Thrombotic 
Microangiopathies
Endothelial cells are crucial players in TMA. Their 
damage is the most important event in the pathoge-
nesis of the disease and lesions are predominant in 
vessels, consisting in microthrombi with red blood cells 
fragmentation in arterioles, capillaries and arteries46. 
It is also important to realize that severity and duration 
of the disease do influence the development of these 
features, either in glomeruli or vessels. The endothelial 
cell aggression commands almost all the morphological 
aspects in the early stages of the disease.
Light microscopy findings in glomerular early lesion 
consists of endotheliosis, the swelling of the glomerular 
endothelium, with subendothelial widening that, depen-
ding of the intensity of the aggression, may occlude the 
capillary lumina. Eventually, bloodless glomeruli (closure 
of capillary lumina) may be observed (Figure 2a). The 
separation of the endothelial cell from the basement 
membrane with production of a new basement 
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Figure 2a
Closure of  lumina and trombosis  of  afferent arteriole with wall 
invasion. HE x200
Figure 2a
Closure of  lumina and 
trombosis of  afferent arteriole 
with wall invasion. HE x200
Figure 2b
Chronic ischemic glomerulus. 
Vessel with a thrombus and 
“mucoid” aspect of the intima. 
Tricrome x 200.
  
Figure 2b
Chronic ischemic glomerulus. Vessel with a thrombus and “mucoid” 
aspect of the intima. Tricrome x 200
Figure 2a
Closure of  lumina and 
trombosis of  afferent arteriole 
with wall invasion. HE x200
Figure 2b
Chronic ischemic glomerulus. 
Vessel with a thrombus and 
“mucoid” aspect of the intima. 
Tricrome x 200.
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membrane gives rise to double contours, best observed 
by PAS or Silver stains. Congested glomeruli, or glome-
rular paralysis, is due to the presence of red blood cells 
in the glomeruli, in cases where there is severe invol-
vement of the efferent arteriole. Fibrin can be detected 
within thrombus or in cases where there is fibrinoid 
necrosis of the afferent arteriole. Exceptionally, cres-
cents may develop in some cases, secondarily to necro-
sis. Additional findings include glomerular capillary 
infiltration by large number of neutrophils, a mesangial 
fibrillary appearance due to edema and mesangiolisis, 
the dissolution of mesangial matrix. The glomeruli in 
biopsies performed later along the natural history of 
the disease (Figure 2b) will display a solid aspect, reflec-
ting a collapse of the glomerular tuft, with thickening 
and wrinkling of capillary walls, as a consequence of 
severe vascular lesions and associated ischemia. The 
migration of mesangial cells to the sub-endothelial 
space will consolidate the double contour pattern, 
sometimes mimicking a membranoproliferative aspect. 
Also, a continuous augmentation of matrix due to ische-
mia will lead to mesangial sclerosis. In far advanced 
disease, the ischemic aspects of glomeruli are more 
frequent: in the chronic ischemic glomeruli there is a 
simplification of the glomerular tuft, which comes smal-
ler, with the resulting widening of the Bowman space 
being filled by collagen.
Various changes may occur in arteries and arterioles 
in TMA. Some cases have mild aggression to the vessels, 
but whenever it happens, it is the severity of the lesions 
of vessels that dictates prognosis. In arterioles, once 
again, endotheliosis induces narrowing of the capillary 
lumen, thrombi may develop, fibrin may invade the 
arteriolar wall and necrosis tend to occur at the hilum 
of the glomerulus. In arteries, swelling of the intima is 
responsible for the intimal mucoid appearance, thrombi 
are present, as is fibrin in the lumen, sometimes inva-
ding the wall. Infiltration of the intima by cells may 
induce a pattern of “onion skin”, the hallmark of evo-
lution towards fibrosis11.
Immunofluorescence findings tend to be scarce and 
inconstant. The majority of biopsies will not display 
deposits. Fibrin in thrombi or areas of fibrinoid necrosis 
of glomerular capillaries and vessels is expected. IgM 
may be seen in parietal vessel walls. In some cases, C3 
or C5b-C9 have been reported in glomeruli, not only 
in aHUS but also in TMAs associated with drug toxicity 
or after hematopoietic stem cell transplantation. It is 
striking why complement is so rarely seen in aHUS 
biopsies, a disease driven by the alternative pathway 
dysregulation. There are two hypotheses to justify this 
point: one is technical; the actual immunofluorescence 
method may not be sufficiently sensitive to label them; 
another hypothesis relates to the time lag between 
the acute phase of the disease and time of biopsy, 
usually a few weeks after presentation and once treat-
ment-induced hematological remission has occurred: 
by then, complement components may have already 
been degraded6,11,47.
Ultrastructural studies of biopsy specimen are rather 
non-specific and affect mainly the endothelial cell, with 
sub-endothelial expansion, swelling and loss of 
fenestration.
Similarly to what was already stated for the clinical 
findings, the reported morphological aspects are sha-
red among TMAs in general, and cannot be used to 
differentiate them. However, for an experience nephro-
pathologist, subtle changes may suggest a specific 
diagnosis. For instance, in aHUS the thrombi are richer 
in fibrin, whereas in TTP the thrombi are full of 
platelets.
Renal biopsy remains an important procedure in the 
evaluation of TMA. As abovementioned, per se it will 
not establish the etiology of any given TMA, nor is it, 
with the current awareness of TMA (aHUS in particular), 
expected to provide the first clue to a TMA or aHUS 
diagnosis, with the occasional exception of TMA occur-
ring in renal allografts. Still, it is critically important in 
ruling out secondary forms, such as TMA in lupus 
nephritis, and establishing a reliable renal prognosis.
 ATYPICAL HUS
  General Overview: Epidemiology, Clinical Presen-
tation and Physiopathology
Atypical hemolytic uremic syndrome is an ultra-rare 
disease. In Portugal, the true incidence and prevalence 
is unknown. In Europe aHUS has an estimated preva-
lence of 2/1,000,000 adults and 3/1,000,000 children. 
This disease can manifest in any age, but usually affects 
predominantly children and young adults. Gender dis-
tribution appears to be similar48,49.
The diagnosis of aHUS is mainly clinical, because as 
previously mentioned, complement abnormalities are 
not uniformly present and secondary TMA forms are 
essentially ruled out on clinical grounds alone. There-
fore, the diagnosis is based on the combination of 
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clinical evaluation and biochemical findings. Additio-
nally, results of genetic testing are not immediately 
available.
The classical presentation is laboratory evidence of 
the classical triad of hemolytic anemia (decreased 
hemoglobin, elevated LDH, decreased haptoglobin, 
schistocytes on blood smear) with Coombs test nega-
tive, thrombocytopenia and acute kidney injury. Howe-
ver, a subacute presentation can occur with proteinu-
ria, acute kidney injury, arterial hypertension with signs 
of TMA on renal biopsy with or without thrombocyto-
penia and hemolysis. Therefore, in every patient pre-
senting with renal insufficiency and low-grade hemoly-
sis the differential diagnosis with TMA needs to be 
considered50.
Extra-renal findings are present in up to 20% of the 
patients. Gastrointestinal involvement (diarrhea, colitis, 
abdominal pain, and pancreatitis) was documented in 
one-fourth of aHUS patients. Also, some of these 
patients have bloody diarrhea. Neurological symptoms 
were also found, as cardiac (acute myocardial infarction, 
cardiomyopathy, heart failure) and pulmonary49,51.
The complement system (Figure 3) is an essential 
part of innate immunity and provides a first-line defense 
against invading pathogens infections and non microbial 
forms of stress. Three distinct activation pathways 
belong to the complement system: the classical, lectin, 
and alternative pathways, all resulting in the formation 
of C3 convertases. The C3 convertases (C4b2a and 
C3bBb) continuously cleaves C3 in an amplification 
loop. The terminal complement cascade is initiated by 
the C5 convertase and generates the membrane attack 
complex inducing cell lysis. The C3 convertase ampli-
fication loop requires rigorous control to prevent unin-
tended tissue inflammation and damage52.
In aHUS, the underlying pathogenesis lies behind 
the alternative pathway dysregulation on host cell 
surface, secondary to complement gene mutations or 
presence of antibodies against complement factors. 
The dysregulation of the alternative complement path-
way can result from either a loss-of-function mutation 
in a regulatory gene (CFH, CFI, MCP and THBD [throm-
bomodulin coding gene]) or a gain-of-function muta-
tion in an effector gene (CFB and C3). Penetrance of 
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Figure 3
The complement cascade
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aHUS in carriers of mutations in some genes is around 
50%53-57.
Also, the presence of autoantibodies against factor 
H (fH)58,59 that interfere with the alternative pathway 
regulation in a similar way to mutations, has been 
reported in aHUS children. Usually the presence of 
antibodies against (anti-fH) is associated with a homo-
zygous deletion of the genes for complement factor 
H-related (CFHR) proteins (CFRH1 and CFRH3)60.
In addition to the mutations in complement proteins, 
some patients with aHUs present mutations in other 
molecules not directly linked to complement system, such 
as mutations in diacylglycerol kinase ε, plasminogen, and 
factor XII (although only in the presence of anti-factor H 
autoantibodies). Some patients have mutations in the 
thrombomodulin coding gene, which has a role in both 
coagulation and complement regulation61,62.
 Diagnostic of atypical Hemolytic Uremic Syndrome
General evaluation
The diagnosis of aHUS relies, firstly, on the proper 
characterization TMA as above mentioned (section II.a). 
Kidney injury is identified as creatinine elevation and 
hematuria or proteinuria. Figure 1 summarizes the 
diagnostic work-up to perform in these patients.
As a priority, TTP needs to be ruled out. An ADAMTS 
13 activity <10% confirms the diagnosis of TTP (see 
Table 1 for sample conditions). Excluding STEC-HUS 
comes next. Screening specifically for E. coli O157:H7 
serotype in stool with sorbitol-MacConkey (SMAC) 
agar is often considered. However, other serotypes 
of STEC have been reported to account for a significant 
fraction of outbreaks21. Therefore, whenever diarrhea 
is present, the direct detection in stool specimens of 
one or two phage-encoded Shiga toxins, Stx1 and Stx2, 
by an enzyme-linked immunosorbent assays (ELISA) 
is preferred as the initial approach. Once stool cultures 
are positive and available, detection of the responsible 
genes, stx1 and stx2, by PCR amplification techniques 
(real-time PCR) using commercial kits, is another pos-
sibility, depending on local availability. In the event 
of a highly suggestive STEC-SHU case but with negative 
ELISA and/or real-time PCR assays for the Shiga toxins, 
bacteria isolated from stool cultures should be refer-
red to the Instituto Nacional de Saúde Doutor Ricardo 
Jorge, Lisboa, for further molecular bacterial DNA 
genotyping63.
Portuguese consensus document statement in diagnostic and management 
of atypical hemolytic uremic syndrome
Table 1
Information for sample collection for analyses in thrombotic microangiopathies
Analyses Sample Transport conditions Aliquots Lab
•  C3; C4
•  serum
•  frozen sample  
(sample should arrive frozen at the Lab)
 
•  All  labs perform these tests
•  Factor H, B, I
•  serum 
•  frozen sample  
(sample should arrive frozen at the Lab) 
2 (10µl each)
•  CHLC – Immunology lab – Clinical 
Pathology
•  CH50;  AH 50
•  serum
•  frozen sample  
(sample should arrive frozen at the Lab)
2 (10µl each)
•  CHP; CHLC, HBA, HSM;  Terceira;  
•  Antibodies
•  Anti factor H
•  serum
•  frozen sample  
(sample should arrive frozen at the Lab) 2 (10µl each)
•  CHLC; CHP
•  MCP (CD46)
•  Flow cytometry
•  all blood
•  sample with EDTA
•  Sample with EDTA  
(should arrive in the same day)
 
•  No lab performs this test in Portugal
•  ADAMTS13 Activity and 
Antigen
•  Antibodies Anti ADAMTS13
• Plasma
•  Sample with citrate  
(sample should arrive frozen at the Lab)
3 (20µl each)
•  CHUC – Haemostasis and Molecular 
Haematology Lab
•  CLHC – Immunology lab
•  Shiga Toxin detection
•  ELISA
•  Real-time PCR
•  Sorbitol-MacKonkey (SMAC)
•  Fresh stool sample
•  Standard stool 
culture enrichment
•  Stool culture with 
selective media
•  Sterile container 
•  For solid phase immunodetection of 
shiga toxins in diluted fecal samples 
(without the need of stool cultures);
•  Requires stool culture enrichment 
before bacterial DNA extraction and 
PCR amplification;
•  Requires stool culture enrichment with 
SMAC: solely identifies the E. coli 
O157:H7 serotype.
 •  Local microbiology lab (see text for 
indications for sending samples to 
Instituto Nacional de Saúde Doutor 
Ricardo Jorge, Lisboa)
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After the exclusion of these two conditions, second-
ary causes of TMA, which will eventually require specific 
treatment, need also to be ruled out (see Figure 1).
Phenotype evaluation of the complement
The levels of complement proteins should be eva-
luated in all patients with TMA and clinical suspicion 
of aHUS, prior to plasma therapy6. In Table 1 we present 
the complement studies which must be carried out in 
these patients.
It should be noticed that in general, low C3 and nor-
mal C4 concentrations in serum suggests complement 
alternative pathway activation. But one must be aware 
that decreased serum C3 level is not specific for aHUS 
and also that normal C3 and C4 concentrations do not 
exclude the diagnosis of aHUS47.
A large decrease in C3 is usually observed with muta-
tions in C3, CFI and CFH genes. Factor B (fB) is a protein 
unique to alternative pathway, and a decrease in levels 
of fB is an indication of activation of alterative pathway. 
Factor I and fH should also be evaluated, since low 
levels of these tend be associated with low C3 levels. 
Quantification of MCP factor (CD46), found to be redu-
ced in 10% of patients with aHUS, can be performed 
by flow cytometry and, importantly, the levels of MCP 
factor are not influenced by plasma therapy47. Recent 
guidelines recommend the evaluation of CD46 surface 
expression by flow cytometry6 but, in Portugal, no lab 
is currently performing this test.
Many complement functional assays and activation 
markers were, in the meantime, developed. CH50 is 
the most used assay to screen complement abnorma-
lities. A low CH50 can result from congenital comple-
ment deficiencies, increased consumption of comple-
ment factors or insufficient syntheses of complement 
factors. AH50 is used to evaluate the alternative path-
way activity. If the test is performed during the acute 
phase of the disease, the AH50 activity is low because 
of consumption of complement cascade components 
47. The KDIGO recommendations are to evaluate CH50 
and AH50 in all patients with aHUS suspicion6.
Additionally, complement activation markers are 
being evaluated, including C3 decay products (C3a, 
C3b), C4 decay products (C4d), C5 decay products (C5a) 
and fB decay products (Ba, Bb). The most interesting 
of these products is the fB decay products, in particular 
Bb. The fB is specific for alternative pathway and ele-
vated levels of Bb fragment with decreased levels of 
fB were reported in patients with aHUS(47, 64). 
However, the results obtained with complement acti-
vation markers are conflicting and not recommended 
in evaluation of these patients, according to interna-
tional guidelines6. These tests are not available in Por-
tugal and there is no evidence to recommend its use.
Human molecular genetics of the complement
Atypical HUS is characterized by dysregulation of the 
alternative complement pathway resulting from either 
a loss-of-function mutation in a regulatory gene (CFH, 
CFI, MCP or THBD) or a gain-of-function mutation in 
an effector gene (CFB or C3)(65, 66). The mutations 
were mainly found in the heterozygous state, and 
approximately 5% of patients have combined muta-
tions, usually in CFH with either CD46 or CFI. Homo-
zygosity for risk haplotypes of CFH (rs3753394, c.1-
-332C>T and rs1065489, c.2808G>T, p.Glu936Asp) that 
tag the disease risk haplotype CFH-H3 and one poly-
morphism in MCP (rs7144, c.*897T>C) that tags the 
MCPggaac risk haplotype have been shown to signifi-
cantly increase disease penetrance and severity(67-69). 
Additional genetic risk factors include a deficiency of 
CFH–related proteins 1 (CFHR1) and 3 (CFHR3), due to 
CFHR1–3 deletion in homozygous state caused by non-
-allelic homologous recombination of CFHR3 and 
CFHR1(70, 71). Finally, recessive mutations in DGKE, 
which encodes diacylglycerol kinase-ε and is expressed 
in endothelial cells, platelets, and podocytes, were 
identified in children with the onset of aHUS in the first 
year of life16.
However, detectable complement abnormalities 
have been described in only approximately 50%–60% 
of patients; therefore, the aHUS diagnosis is based on 
clinical criteria and the exclusion of a severe ADAMTS13 
deficiency (<10%) and STEC-HUS 72.
The advent of next-generation sequencing (NGS) 
allows simultaneously sequencing of large gene panels 
and generates competitive results at a lower cost and 
in a shorter amount of time.
Therefore, the strategy for TMA diagnosis should be 
based on a workflow that includes the measure of 
ADAMTS13 activity and screening of ADAMTS13 and 
complement genes using a NGS gene panel – ADA-
MTS13, CFH, CFHR1, CFHR3, CFHR4, CFHR5, CFI, CFB, 
C3, THBD and DGKE (see Annex 1 – Human molecular 
genetics: information for sampling and where to send 
and Annex 2 – Informed consent for genetic testing).
The NGS-targeted gene panels have changed the 
paradigm of routine molecular studies. In the face of 
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the multiple genetic changes found in every patient, 
the critical challenge was discriminating disease-asso-
ciated variants (historically referred as mutations) from 
the broader background of variants present in all 
patients’ genomes(73-78). The prediction of pathoge-
nicity of the genetic variation has become crucial for 
understanding the great inter-individual variability of 
these patients.
According to the practice guidelines for the evalua-
tion of pathogenicity recently published by the Ameri-
can College of Medical Genetics and Genomics and the 
Association for Molecular Pathology77 the following 
criteria must be evaluated: 1) whether the variant was 
a stop/frameshift variant, which was considered to 
most likely be disease causing, 2) co-segregation in the 
family, 3) whether the variation had been previously 
identified in international databases, 4) in silico evalu-
ation and 5) presence of the second mutant allele in 
the case of autosomal recessive inheritance. Thus, the 
variants will be classified as pathogenic, likely patho-
genic, uncertain significance, likely benign or benign 
based on the available evidence.
This approach provides an accurate molecular analy-
sis; however, its interplay with a detailed clinical data 
registry sustained by a multidisciplinary team is crucial 
for a correct TMA differential diagnosis (see Annex 3 
– Clinical information).
 Outcome
The availability of eculizumab has significantly modi-
fied the prognosis for patients with aHUS. With PEX 
alone, the mortality was about 10% in the first episode 
and more than 50% of the patients needed dialysis 
during the first year of the disease48,49.
Clinical outcomes remain critically dependent on the 
genotype. Table 2 summarizes patient survival as well 
both native and graft kidney survivals according to 
genotype, based on which we can stratify the risk of 
death or End-Stage Renal Disease (ESRD), recurrence 
and transplant relapse. This information was compiled 
from several published aHUS cohorts48,49,69. Geno-
phenotype correlations in a cohort of 273 aHUS patients 
revealed49 that complete remissions were more com-
mon with THBD and MCP mutations (62% and 90% 
respectively), and that patients displaying MCP muta-
tions also spontaneously remitted more frequently. 
Poor responses were observed in patients with CFH 
and CFI mutations, with a complete remission rate of 
only 5% and 12.5%, respectively. Additionally, partial 
remission was observed in more than 50% of treated 
patients with CFH mutations or in the presence of anti-
fH antibodies. Overall, better treatment responses were 
observed in children than adults (78% vs 53%) and 
mortality or ESRD after plasma therapy was high, espe-
cially with CFH (77%) and CFI (67%) mutations49. In 
another retrospective analysis of a cohort of 214 
patients with aHUS, more than half of adult patients 
with CFH mutations developed ESRD after the first epi-
sode, despite treatment with high volume PEX48.
Similarly, the outcome of kidney transplantation is 
influenced by genetics: 60% of patients had recurrent 
disease, with an 80–90% of graft loss, depending on 
the causative mutation(79, 80). Once again, mutations 
in CFH are associated with a higher risk of recurrence 
or graft loss after transplantation (75-90%), particularly 
those related to abnormalities in terminal 3’ or gene 
conversions between CFH and CFHR1 (hybrid gene CFH/
CFHR1)81. In two French case series(51, 82) the rate of 
post-transplant aHUS recurrence in patients with CFH 
mutations was around 75–80% in 5 children and 16 
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Table 2
Clinical outcomes of patients with aHUS (before eculizumab)
Gene
Risk of death or ESRD  
in 1st year 
Risk of relapse
Death risk or ESRD 
3-5 years
Kidney Transplant
 Risk of recurrence
CFH 50-70% 50% 75% 75-90%
CFI 50% 10-30% 50-60% 45-80%
MCP 0-6% 70-90% 6-38% <20%
C3 60% 50% 75% 40-70%
CFB 50% 3/3 75% 100%
THBD 50% 30% 54% a)
Anti-FH 30-40% 40-60% 35-60% 30%
a) Insufficient data
Abbreviations: Anti-FH – anti-complement factor H antibodies; CFB – complement factor B gene; CFH – complement factor H gene; CFI – complement factor I gene; ESRD – end-stage 
renal disease; MCP – membrane cofactor protein gene; THBD – thrombomodulin gene. 
Adapted from Campistol et al5 and Noris et al135.
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adults who received 6 and 17 renal transplants, res-
pectively. The same recurrence rate was noted in a 
2006 meta-analysis of 36 renal transplantations in 27 
patients with aHUS associated with CFH mutations, 
leading to a graft loss in 93% of patients79. In aHUS 
patients with CFI mutations, the post-transplant recur-
rence rate is also high and associated with poor prog-
nosis56,83,84. More than half of cases with mutations 
in CFI had an additional genetic susceptibility for aHUS, 
which negatively impacted kidney survival85. Patients 
with MCP mutations are expected to have a low risk 
of post-transplant aHUS recurrence (<20%) because 
MCP is a membrane-bound protein, expressed on endo-
thelial cells and, therefore, transplantation will restore 
normal renal endothelial MCP function83. However, a 
recent large study69 revealed an unexpected recurrence 
of disease after transplantation in some carriers of MCP 
mutations. This is probably explained by the fact that 
a significant proportion of patients with mutations in 
MCP also carried mutations in genes encoding circula-
ting complement factors69. Because mutations in other 
genes are rare, less data is available about the risk of 
recurrent disease. Nevertheless, existing evidence 
suggests significant risk of recurrent associated with 
mutations in C3 and CFB, 60% and 100%, respectively, 
with a high risk of graft failure on recurrence(79, 86). 
The risk of post-transplant recurrence in patients with 
THBD mutations is not well-established, because throm-
bomodulin exists both in membrane bound and soluble 
forms, hence, it is not possible to reliably predict the 
risk of post-transplant recurrence in carriers of these 
mutations. Considering the available studies(87-89) 
THBD mutations may favor recurrence after kidney 
transplantation. Concerning patients with anti-fH anti-
bodies, the risk of post-transplant aHUS recurrence 
seems to be related to high and persistent titers of 
antibodies(59, 82). No posttransplantation recurrence 
has been observed to date in patients with DGKE muta-
tions16. Finally, data on the rate of recurrent aHUS after 
transplant in patients with no identifiable pathogenic 
alleles is sparse. Overall, the risk seems to be lower 
(30%)82.Therefore these patients have to be considered 
at medium risk of recurrence.
 Treatment of atypical HUS
Administration of eculizumab is recommended as first 
line treatment in paediatric patients with suspected 
aHUS. Taking into account the technical difficulties of 
PEX in paediatric patients and potential complications, 
in addition to the superiority of eculizumab for the recov-
ery of renal function, early first-line treatment with 
eculizumab is recommended in this population and the 
use of plasma exchange should be completely avoided.
For adult patients, in the presence of an unequivocal 
diagnosis of aHUS we recommend the use of eculizumab 
as first line therapy. Patients presenting with a TMA of 
uncertain etiological diagnosis, we recommend starting 
PEX. Once secondary causes of TMA, STEC-TMA and 
PTT have been excluded, a presumptive diagnosis of 
aHUS can be assumed in these cases, and if the patient 
remains plasma exchange dependent or displays plasma 
resistance, eculizumab is to be initiated.
Plasma therapies in aHUS
Both plasma exchange and plasma infusion (PI), by 
the administration of large volumes of fresh frozen 
plasma, can provide functional complement-regulating 
proteins. PEX has the advantage of removing dysfunc-
tional complement factors, as well as anti-fH antibodies 
and potential inflammatory molecules that might result 
from endothelial injury, while reducing the risk of volu-
me overload5,90-92.
The use of PEX in the setting of aHUS was attempted 
for the first time in 197993. In the next years, other 
case reports and small series of patients successfully 
managed with PEX have been described90. However, 
some of those reports included TMA secondary to other 
conditions. Furthermore, the role of complement in 
the pathogenesis of aHUS was not yet established, 
consequently no genetic information was available, and 
we can only assume the presence of aHUS based on 
the exclusion of other known causes of TMA. Still, some 
degree of improvement was observed in about 87% of 
the patients in a disease with a previous high morbidity 
and mortality rates90. Over the next few years, early 
and intensive, with high volume PEX was empirically 
used in the treatment of aHUS92,94,95. Potential com-
plications associated with PI and PEX are more common 
in children than in adults and include hypotension, 
allergic reactions, nausea and vomiting, hypocalcaemia 
and catheter-related complications96,97.
Though actual recommendations advocate first line 
therapy with eculizumab particularly in children5,6,16, 
PEX still has its role in the management of aHUS patients. 
Eculizumab is not available (or promptly available) in 
every center. When a delay in eculizumab administration 
is expected, PEX should be initiated within the first 24 
hours, considering the poor prognosis associated with 
late treatment6,16,94. Patients with complete hemato-
logical and renal recovery after PEX may not require 
switching to eculizumab5,16. PEX is also recommended 
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in the presence of anti-fH antibodies in combination with 
immunosuppression given the favorable outcome on 
renal function and mortality16,91,98-102. In the presence 
of severe disease, with coma or seizures, and while TTP 
is not yet ruled out by the presence of ADMTS13 activity 
> 10%, PEX should also be considered6.
When PEX is the selected therapy option, the repla-
cement fluid should be fresh frozen plasma in order to 
provide functional complement factors and the volume 
should be 1.5 of plasma volume (60-75ml/Kg). Different 
treatment schedules have been reported in the litera-
ture and cannot be compared. It is recommended to 
maintain treatments until normal platelet count is 
obtained, hemolysis stops and sustained improvement 
in renal function is observed. Protocols of 5 daily treat-
ments initially, followed by 5 treatments per week for 
2 weeks and then 3 treatments per week for the next 
2 weeks have been proposed. Subsequent treatment 
should be assessed on individual basis5,16.
Terminal complement blockage
The complement system offers multiple potential 
therapeutic targets, and several drugs acting on the 
activation pathways, the anaphylatoxins, the amplifi-
cation loop and the terminal pathway, have been deve-
loped and entered preclinical and clinical trials103. 
Blocking the terminal pathway offers the possibility of 
having a potent inhibitory effect on the cascade, while 
at the same time allowing the upstream components 
to retain some of their physiological functions, such as 
the removal of apoptotic and necrotic cells and solu-
bilization of immune-complexes104.
Eculizumab4 is a humanized monoclonal IgG2/4 
kappa antibody against C5 that blocks cleavage of the 
terminal complement protein C5 into the proinflam-
matory C5a and lytic C5b-9. After being developed in 
the 1990s, it was tested in a range of inflammatory 
conditions in early clinical trials. The most impressive 
efficacy was found for Paroxysmal Nocturnal Hemoglo-
binuria (PNH), and it was for this condition that it was 
firstly approved for clinical use in 2007 by the FDA (Food 
and Drug Administration) and EMA (European Medical 
Agency). As another prototypical disease resulting from 
complement dysregulation, aHUS was the next obvious 
candidate for clinical use of eculizumab. After successful 
case reports105,106, and the preliminary reports of two 
prospective clinical trials107,108 of primarily adult 
patients, either with evidence of progressing TMA or 
with long disease duration, demonstrating efficacy and 
safety of eculizumab in aHUS, it became in 2011, the 
first and only approved treatment for aHUS.
In 2016, the first and largest study of eculizumab to 
treat severe aHUS in an exclusively adult population 
was published. An open-label single-arm phase 2 trial, 
with 41 aHUS adult patients receiving eculizumab, 
highlighted its benefits in improving hematological, 
renal and quality of life paramaters, dialysis disconti-
nuation and transplant protection, after a 26-week 
treatment period109.
Although there has never been a randomized con-
trolled trial on eculizumab in aHUS, the mechanistic 
rationale and the high morbidity and mortality asso-
ciated to this disease, justified that comparison with 
historical controls is sufficient enough for the recom-
mendation of its use. And clearly, the prognosis of 
aHUS has been transformed: full recovery of renal 
function is now expected, other than in those who 
present late in the course of disease. KDIGO guidelines 
recommends that all patients with a clinical diagnosis 
of aHUS are eligible for treatment with a complement 
inhibitor6.
The recommended dosing schedule for eculizumab 
in aHUS is the one reported in the trials (Annex 4 – 
Eculizumab dosing schedule), and although options for 
altered dosing have been considered such as the mini-
mal dose required to achieve complement blockade or 
a discontinuation dosing schedule, there is still not 
enough data to support either option108,110.
In patients with ant-fH mediated aHUS, eculizumab 
should be used in patients with severe injury of vital 
organs16, in association with immunosuppression. Ecu-
lizumab discontinuation should be guided by antibodies 
titers6,16.
Prophylaxis of meningococcal infections
All patients should be immunized against meningo-
coccal infection (including type B) given the risk inher-
ent to the treatment with eculizumab. Ideally, the vac-
cination should be given at least two weeks before 
treatment or getting clearance for transplantation. 
However, eculizumab initiation should not be delayed 
because lack of previous immunization and this circum-
stance antibiotic prophylaxis is mandatory up two 
weeks after vaccination6. Currently, in Portugal, the 
following vaccines are available with the preconized 
schedules for the general population111:
a)  Conjugated tetravalent meningococcal vaccine – 
MenACW135Y (Nimenrix®, Menveo®)
b)  Meningococcal B vaccine – MenB (Bexsero®, 
Trumemba®)
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In addition to invasive meningococcal disease, trea-
ted individuals are at increased risk of serious infection 
by other capsulated bacteria namely Haemophilus 
influenza type b and Streptococcus pneumoniae. 
Patient’s vaccination status must be confirmed in accor-
dance with the recommendations of the Direção Geral 
da Saúde (DGS)112.
The working group therefore recommends the fol-
lowing scheme:
–  Meningococcal vaccination (mandatory): Men-
ACW135Y and MenB
–  Others (recommended): Pn13, Pn23, Hib, Influenza
Since the carriage rate of meningococci is the highest 
in adolescents and young adults (up to 30% between 
age 16 and 24) vaccination of susceptible household 
close contacts may be also considerer (siblings and 
parents)16.
Antibiotic prophylaxis
The current vaccination scheme is not effective in 
protecting against all meningococcal serotypes. Also, it 
is unknown if anti-meningococcal antibodies are protec-
tive in the setting of complement blockade. Therefore, 
giving prophylactic antibiotic treatment to all patients 
under eculizumab therapy is recommended113.
Prophylactic treatment for adults and children > 12 
years old is to be performed with amoxicillin 500 mg orally 
twice daily; for children two-12 years of age, 250 mg orally 
twice daily; and < two years old 10 mg/kg twice daily. In 
the presence of penicillin allergy, a macrolide can be used: 
for children and adolescents, we recommended azi-
thromycin at a dose of 5 mg/kg/day. The antibiotic pro-
phylaxis should be used during throughout the treatment 
and until 60 days after eculizumab treatment has ended6.
Neither vaccines nor antibiotic prophylaxis guaran-
tee full protection114, hence the importance of patient/
family educations about signs of meningococcal infec-
tion and the availability of an information card to be 
carried by patients or their care-giver16.
Pregnancy
Recent studies, including those on PNH patients, 
showed acceptable outcomes with a high rate of fetal 
survival and a low rate of maternal complications, 
although preeclampsia and HELLP syndrome have not 
been prevented in 2 and 1 reported cases respectively, 
and higher doses of eculizumab than generally recom-
mended had to be used during pregnancy43,44.
Monitoring disease activity and therapeutic efficacy
Complement blockade is obtained within 1h of the 
first dose. With the recommended treatment scheme, 
most patients will have full complement blockade in 
between consecutive doses. Special attention should 
be paid to children and pregnant women who could 
need an adjustment to the usual dose5,16. Also, patients 
with massive proteinuria may need higher doses of 
eculizumab.
During the treatment, monitoring relies on regular 
measurement of CH506, consisting in the use of acti-
vated sheep erythrocytes which are mixed with dilu-
tions of patients’ serum to identify the dilution requi-
red to lyse 50% of available sheep erythrocytes. 
Eculizumab treatment suppresses CH50 activity, so in 
these patients is expected to obtain a CH50 < 10 % of 
normal value, using this technique47,115. Easier 
hemolytic or enzyme-linked immunosorbent assays 
are currently commercially available, and normal range 
is assay dependent. A limitation of this test is that 
CH50 cannot be used in patients with complete fH 
deficiency (e.g. of homozygous CFH mutation) in whom 
CH50 levels are permanently undetectable regardless 
treatment status115.
Eculizumab trough levels could be measured in patients 
under this treatment and is expected to have full com-
plement blockade with trough levels above > 100 μg/
mL6,16. In Portugal, no lab yet performs this technique.
Eculizumab discontinuation
One of the most controversial issues concerning the 
use of eculizumab in aHUS, is the duration of treatment. 
Some current recommendations suggest that eculi-
zumab should be prescribed indefinitely5. Supporting 
this notion is the fact that aHUS is a chronic disease 
and TMA manifestations are unpredictable and can lead 
to irreversible and potentially life-threatening complica-
tions116. On the other hand, continued therapy with 
eculizumab carries an increased risk of meningococcal 
infection, the need for prolonged prophylactic antibio-
therapy and is very costly. In fact the optimal duration 
of eculizumab treatment is presently unknown6. In the 
original eculizumab trials108 a continued and time 
dependent improvement of kidney function was 
observed up to 12 months (quick increase in estimated 
glomerular filtration rate (eGFR) in the first 26 weeks 
and a trend towards stabilisation thereafter). In one of 
the trials (trial 1) 4 out of 5 patients that were dialysis 
dependent recovered autonomous kidney function. 
Based on these observations we follow other consensus 
boards5,6,117 and recommend that eculizumab should 
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be maintained for a minimum of 6-12 months; also, in 
patients with acute renal failure in need of renal 
replacement therapy, eculizumab treatment is recom-
mended for at least 3 months before establishing the 
final diagnosis of end stage renal disease.
If suspension of eculizumab therapy is being consi-
dered, the risk of relapse should be discussed with the 
patient. A recent analysis of discontinuation of eculi-
zumab therapy in patients with aHUS revealed that 
treatment was discontinued in 47% of the patients 
included in the original clinical trials and in 26% of the 
patients included in aHUS registries116. Relapse rates 
ranged from 20% to 31% and in 5%, organ losses were 
reported116. This analysis was unable to establish any 
definitive predictor of relapse, although patients with 
relapses seemed to have a higher proportion of CFH 
gene pathogenic variants116. The authors consider that 
until novel tools enabling a more robust risk stratifica-
tion and adequate monitoring of complement activa-
tion and disease activity are made available, the option 
to discontinue eculizumab therapy will not be an evi-
dence-based decision116.
However the analysis of the French aHUS Registry, 
including 108 patients, identified 38 in which eculizu-
mab was suspended (35%); of these, 12 (32%) relapsed 
with a median time to relapse of 7,5 months (total 
follow up time was 22 months)109. Of the 12 patients 
that relapsed, 8 (67%) had CFH gene pathogenic variants 
(compared with only 3 nonrelapsers with CFH patho-
genic variants, p=0.002) and 4 (33%) had MCP patho-
genic variants (compared with 4 nonrelapsers with MCP 
pathogenic variants, p=0,2). Importantly, all patients 
that relapsed had an identified pathogenic variant in 
one of the complement genes (p=<0.001)109.
A key aspect of this analysis was that eculizumab 
was resumed in all relapsing patients within 48 hours, 
leading to a good therapeutic response: within the 
follow-up period no changes in eGFR or relapses were 
reported109.
In conclusion, the optimal duration of eculizumab 
treatment in patients with aHUS is currently unknown. 
If suspension is being considered, a risk analysis of relap-
se should be made. Presently, the best available data 
supporting any decision resides on the published analysis 
of the French aHUS Registry: in patients with no muta-
tions or MCP mutations eculizumab discontinuation can 
be considered; in patients with CFH pathogenic variants 
any decision must take in consideration the high risk of 
relapse; and in patients with anti-fH antibodies, 
eculizumab discontinuation can be considered only when 
titers have been significantly reduced109.
In all cases of discontinuation of therapy patients 
must be followed closely. Regular blood and urine tests, 
including serum creatinine, haemoglobin, platelet 
count, schizocytes, lactate dehydrogenase, haptoglobin 
and proteinuria-to-creatinuria ratio, should be per-
formed every week for first month, subsequently every 
two weeks for 3 months and monthly thereafter109; 
regular blood pressure monitoring is also suggested. 
Patients should consult their physician in case of poorly 
controlled blood pressure or any intercurrence that 
might trigger the disease (e.g. infection, surgery, preg-
nancy). Importantly, in case of a relapse, eculizumab 
therapy should be quickly resumed.
Immunosuppressive therapy
The use of immunosuppression has shown benefit 
in children with anti-fH antibodies. Steroids in combina-
tion with cyclophosphamide or rituximab following PEX 
reduce antibody titers, prevent disease relapses and 
improve renal survival(69, 85-87). In a cohort of 138 
Indian children with anti-fH antibodies, early combined 
therapy with PEX and induction immunosuppression 
was significantly associated with better outcomes in 
the multivariate analysis (OR 0,22, 95% CI 0,07–0,76; 
P = 0,016). One case report of an adult successfully 
treated with PEX followed by steroids and rituximab 
has also been described88.
Kidney transplantation
Kidney transplantation should be delayed until at 
least 6 to 12 months after the start of dialysis because 
renal recovery may occur several months after starting 
eculizumab118,119. The resolution of hematological and 
other extrarenal TMA manifestations is a prerequisite 
for transplantation.
Recurrence of aHUS following renal transplantation
Post-transplant aHUS recurrence is usually an early 
event, with 60% of cases occurring within the first month 
after transplantation79. This higher risk of early recur-
rence (Figure 4) may relate to endothelial activation by 
ischemia-reperfusion injury, drugs (e.g. CNI and mTOR 
inhibitors), infections and alloimmune responses (e.g. 
donor specific antibodies). Although early recurrence is 
most frequently seen, late recurrence, up-to several 
years after transplantation, has also been reported120.
More important, the risk for posttransplantation 
recurrence is dictated by the underlying genetic defects 
(see above, section c. Outcome) and the recurrence 
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in previous grafts117. According to this information, the 
risk of recurrence of aHUS can be stratified for patients 
who are candidates for renal transplantation (Table 3).
De novo TMA following renal transplantation
De novo post-transplant TMA (Figure 5) can develop in 
the absence of previous aHUS or any known susceptibility 
factor for aHUS. However, approximately 30% of patients 
who develop de novo post-transplant TMA carry mutations 
in complement regulatory proteins encoding genes82.
Post-transplant immunosuppression regimens
Several strategies related to immunosuppression 
regimens have been attempted to prevent recurrence 
of aHUS in the kidney grafts.
Treatment with CNI, cyclosporine (CsA) or tacroli-
mus, are reported to be associated with post-transplant 
TMA121,122, the risk being apparently higher for CsA 
(up to 14% of patients in one series)121. The use of 
mTOR inhibitors bears a greater risk for post-transplant 
TMA and it was shown that early use of mTOR inhibitors 
is an independent risk factor for the development of 
TMA123, with CNI having a synergic effect124.
Data on the post-transplant immunosuppressive 
regimen and the risk of recurrent aHUS is controversial. 
A small study suggested that the early use of CsA increa-
sed the risk of aHUS recurrent in adults125, but analysis 
of a larger pediatric cohort failed to confirm it126. The-
refore, avoidance of CNI treatment is generally not 
believed to reduce the risk of recurrent aHUS79.
Immunosuppression based on belatacept could be 
followed depending on the immunological risk of each 
patient, although, until now, no conclusive data are 
available in the literature.
Living kidney donation
Living related donor transplantation has traditionally 
been contraindicated for patients with aHUS, because 
it associates with a risk for recurrence in the recipient 
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Figure 4
Strategies for prevention of recurrence of aHUS in kidney transplantation
Figure 4 – Strategies for prevention of recurrence of aHUS in kidney transplantation
Abbreviations
CNIs: Calcineurin inhibitors ; CMV: cytomegalovirus; DSA: donor-specific antibodies;  mTORi: mammalian target of
rapamycin inhibitors;
Abbreviations: CNIs – Calcineurin inhibitors; CMV – cytomegalovirus; DSA – donor-specific antibodies;  mTORi – 
mammalian target of rapamycin inhibitors
Table 3
Recipient risk assessment of aHUS recurrence in post-transplant
High risk os recurrence Moderate risk of recurrence Low risk of recurrence
•  Previous early recurrence in the same individual or 
within family
• Mutations is CHF, NAHR in CFH region
• Gain-of-function mutations in C3 and CFB
•  Isolated CFI mutation
•  Mutations of uncertain functional significance
• No identified mutation
•  Persistent anti-fH antibody
•  Isolated MCP mutation
• Long-term negative anti-fH antibody
Abbreviations: C3 – complement component 3 gene; CFB – complement factor B gene; CFH – complement factor H gene; CFI – complement factor I gene; fH – factor H; MCP – 
membrane cofactor protein gene; NAHR – non-allelic homologous recombination.
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and de novo disease in the donor, if the former carries 
an at-risk genetic variant127,128. For the same reason, 
any potential donor with evidence of complement dys-
regulation should be excluded.
However, if an at-risk genetic variant is detected in 
the patient, it will be possible to consider living related 
donation (Figure 6), in case the donor does not carry 
the genetic variant and has a normal complement phe-
notype. Therefore, it is mandatory to perform a com-
plete genetic screen in donors5,117.
If related donor and the recipient share any genetic 
factor of susceptibility for aHUS or if mutations have 
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Differential diagnosis of TMA in kidney transplantation
Figure 5 - Differential diagnosis of TMA in kidney transplantation.
Abbreviations: aHUS, Atypical hemolytic uremic syndrome;  CNIs, Calcineurin inhibitors; MAHA, 
microangiopathic hemolytic anemia;  mTORi, mammalian target of rapamycin inhibitors; TMA,  
thrombotic microangiopathy.
Abbreviations: aHUS – Atypical hemolytic uremic syndrome; CNIs – Calcineurin inhibitors; MAHA – microangiopathic hemolytic anemia; mTORi – mammalian target of rapamycin 
inhibitors; TMA – thrombotic microangiopathy.
Figure 6
Differential diagnosis of TMA in kidney transplantation
Figure 6 - Living donor selection in kidney transplantation
Abbreviations: aHUS – Atypical hemolytic uremic syndrome; CNIs – Calcineurin inhibitors; MAHA – microangiopathic hemolytic anemia; mTORi – mammalian target of rapamycin 
inhibitors; TMA – thrombotic microangiopathy.
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not been identified in the recipient, living donor trans-
plantation should not be attempted5,117,128. In addi-
tion, living donor transplantation should only be con-
sidered if eculizumab is available5.
Terminal complement blockage in renal transplantation
Individual assessments of the recurrence risk based 
on complement investigations and recurrence in pre-
vious grafts may be used to guide the therapeutic stra-
tegy in renal transplant candidates (Table 3).
Currently, it is recommended that patients at high 
risk of aHUS recurrence should receive prophylaxis 
with eculizumab prior to surgery and thereafter 
(pre-emptive)5,6,16.
The efficacy and security of such a prophylactic regi-
men was studied in a series of treated French patients 
were absence of recurrence as well preservation or 
renal function are reported128, as well in case-reports, 
mainly in the pediatric setting89,129-132.
In patients having not received prophylaxis with 
eculizumab, blockade of terminal complement may still 
be used as a high efficacious rescue treatment for aHUS 
post-transplant recurrence (on-demand)128. Treatment 
for the recurrence of aHUS in patients receiving renal 
transplants should be performed similarly as for aHUS 
affecting native kidneys5,128.
Relevant for this discussion is the publication of a 
recent cost-effectiveness analysis using a decision 
analytical approach that was used to compare alterna-
tives for aHUS patients with ESRD133, namely; 1) dialysis 
treatment, 2) kidney transplantation, 3) kidney trans-
plantation with eculizumab therapy upon recurrence 
of aHUS, 4) kidney transplantation with eculizumab 
induction consisting of 12 months of prophylaxis and 
5) kidney transplantation with lifelong eculizumab pro-
phylaxis. The authors concluded demonstrated that 
adding eculizumab resulted in a substantial gain in 
quality-adjusted life years (QALYS) compared to dialysis, 
but when compared to eculizumab administered upon 
recurrence, neither the drug induction nor lifelong 
eculizumab prophylaxis resulted in more QALYs, but 
did increase the overall costs. Therefore, the authors 
concluded that giving eculizumab upon recurrence of 
aHUS is more acceptable133.
Also, Duineveld et al134 describe their experience 
with kidney transplantation in patients with aHUS, 
without prophylactic eculizumab. They used a protocol 
with living kidney donors to limit ischemia-reperfusion 
injury, together with an immunosuppressive regimen 
comprising basiliximab, prednisone, high-dose myco-
phenolate mofetil, and tacrolimus dosed to target 
lower-than-usual blood concentrations. Sixteen of the 
17 patients treated were at high risk for posttransplan-
tation recurrence. During follow-up ranging from 7 to 
68 months after transplantation, only 1 patient treated 
with their protocol had clinical signs of recurrence. 
Eculizumab treatment in this patient induced hemato-
logic remission but only a partial improvement in trans-
plant function. Although these results open the discus-
sion if posttransplantation eculizumab therapy should 
change from a prophylaxis strategy to a rescue approa-
ch, several limitations were pointed, namely the small 
cohort size and relatively short-term follow-up.
In spite of those analysis133 and data134 the working 
group recommends that until further data is presented, 
recommendation of national and international societies 
should be followed5,6,16 namely, prescribing eculizu-
mab based on (genetic) risk stratification analysis.
Eculizumab is also effective in treating aHUS in 
patients with non CFH mutations5,128; therefore it is 
predicted that the response to eculizumab was inde-
pendent of mutation status. Recurrence does occur in 
patients in the absence of an identified abnormality 
and therefore these patients have to be considered at 
medium risk of recurrence. Patients with no identifiable 
mutation have been shown to respond to eculizumab 
treatment128.
Another important question is the optimal duration 
of prophylactic eculizumab therapy after transplanta-
tion. In patients with high-risk mutations or who have 
experienced a recurrence in a previous graft, anti-C5 
therapy should not be discontinued117,128,135.
In patients with moderate risk, prophylactic treat-
ment may be discontinued after a long recurrence-free 
period117, being patients closely monitored.
The working group recommends (Figures 4, 5, 6 and 
Table 3):
a) The genetic profile of the complement system is 
used to stratify the risk of aHUS recurrence after 
transplantation and to predict graft survival.
b) The decision to use anti-complement therapy during 
transplantation should be based on recurrence risk.
c) Patients with high or moderate risk of recurrence 
should be offered prophylactic eculizumab 
treatment.
Ana Azevedo, Bernardo Faria, Catarina Teixeira, Fernanda Carvalho, Gisela Neto, Josefina Santos,  
Maria do Céu Santos, Nuno Oliveira, Teresa Fidalgo, Joaquim Calado
Port J Nephrol Hypert 2018; 32(3): 211-232    229
d) Prophylactic eculizumab therapy should be rec-
ommended in patients with a high risk of post-
transplantation aHUS recurrence and should be 
initiated prior to surgery at day 0 and include an 
additional dose at day 1.
e) Patients at low risk should be warned of the risk 
of recurrence and monitored closely.
f) There is a relative contraindication to living related 
donation but this can be considered in certain 
conditions, and only be considered if eculizumab 
is available. Kidney transplantation remains inad-
visable if the donor shares a genetic susceptibility 
factor with the recipient or if no mutations have 
been identified in complement genes.
g) In the absence of evidence that CNI usage increas-
es the risk of recurrent aHUS, these drugs should 
be included in immunosuppressive post-trans-
plant protocols.
h) Tacrolimus is recommended due to the lower rate 
of post-transplant TMA reported.
i) The use of anti-IL2 receptor blocking antibody, 
anti-proliferative agent and steroids should be as 
local protocols.
j) mTOR inhibitors should be avoided in post-trans-
plant in patients at risk of recurrent aHUS.
  CONCLUSIONS AND FUTURE 
PERSPECTIVES
Twenty years have elapsed between the characte-
rization of the first CFH mutations in aHUS patients and 
the widespread availability of a highly efficient therapy 
for this entity. During that period, translational research 
programs that brought together physicians and biome-
dical researchers, molecular biologists and immunolo-
gists in particular, have clarified the alternative com-
plement pathway dysregulation that underlies aHUS. 
And in the end, it was biological plausibility that enabled 
the introduction of a successful targeted therapy.
But target therapy is not equivalent to personalized 
medicine and, as such, a major a concern for clinicians is 
prescribing eculizumab for patients that may no longer 
benefit from terminal complement blockage. In order to 
settle this, an assay that reliably assesses disease activity 
is in great demand. Such a test has to be reproducible 
and easy to implement in routine immunology labs. A 
reported ex vivo endothelial complement deposition assay 
that requires cell culture facilities only available in research 
or academic institutions is, for example, an unrealistic 
option136. Such a test will help us in establishing treatment 
duration, since it became clear that in a significant fraction 
of patients, terminal complement blockage needs not to 
be prescribed for life. Finally, and considering what has 
happened with other recombinant molecules for medical 
use, eculizumab biosimilars, pegylated or long-acting for-
mulations, as well monoclonal, peptides or small chemi-
cally synthetized compounds targeted to upstream com-
plement mediators are expected to enter the market. 
Since costs and patient convenience always impact phy-
sicians’ practice, the way those will change current gui-
delines is unpredictable (for details check aHUS pipeline 
2017 at http://www.ahusallianceaction.org/ahus 
-therapeutic-drugs-research-development/).
It is now apparent that abnormalities of alternative 
complement pathway play a role in a larger fraction of 
renal diseases than what was initially suspected, 
somehow overshadowing the importance of the more 
traditional (and) classical pathway. They range from the 
inconspicuous role in renal disease progression mediated 
by acidosis, in which disruption of the internal thioester 
bond of C3 by ammonia promotes tubulointerstitial 
fibrosis137, to IgA nephropathy, where deletion of the 
CFHR1-3 locus was found to be protective138, or ANCA 
associated vasculitis for which C3 hypocomplementemia 
is associated with worst renal prognosis139 and C5a 
receptor antagonism is being considered as a therapeutic 
option140. Probably the most proxy is, of course, C3 glo-
merulopathy (C3G). An increasing number of reports 
depicting abnormalities in the complement genes, mos-
tly involving large rearrangements within the CFH-CFHR 
locus (with and without anti-fH antibodies), is being 
matched by similar increasing number of reports detai-
ling the off-label use of eculizumab in C3G141.
Atypical Hemolytic Uremic Syndrome, a rare kidney 
disease, allowed the nephrology community to clinically 
explore and manipulate the complexity of the comple-
ment system in the best interest of our patients. Let 
us hope that the insights gained with this journey can 
expand our interventional knowledge on more preva-
lent nephropathies.
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